Sign In
Buy ISEE
$39.95
+0 (+0%)
At Close: Oct 09, 2023
Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA)
09:00am, Wednesday, 20'th Sep 2023
GA is a form of age-related macular degeneration (AMD) that causes irreversible vision loss, affecting approximately 1.5 million people in the United States 1,2 Eric and his mother, Jamey, are sharing
GATHER2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham IZERVAY 24-month safety data were consistent with 12-month resu
European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy
07:30pm, Thursday, 17'th Aug 2023
TOKYO , Aug. 18, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the European Medicines Agency (EMA) has accepted for regulatory r
IZERVAY is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials IZERVAY slowed lo
Deep Track Capital, LP Acquires New Stake in Terns Pharmaceuticals Inc
06:02pm, Friday, 28'th Jul 2023
Deep Track Capital, LP (Trades, Portfolio), a prominent investment firm, recently made a significant move in the stock market by acquiring a new stake in Terns Pharmaceuticals Inc. This article will d
Astellas Completes Acquisition of Iveric Bio
07:00pm, Tuesday, 11'th Jul 2023
TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisi
Astellas Pharma CEO Says Confident of Iveric Bio Drug Approval
08:58pm, Monday, 01'st May 2023
Naoki Okamura, chief executive officer of Japanese drugmaker Astellas Pharma Inc., discusses his company's decision to acquire Iveric Bio Inc., a developer of drugs to treat age-related blindness, f
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ISEE, MDWT, RXDX, UNVR
05:22pm, Monday, 01'st May 2023
NEW YORK, May 1, 2023 /PRNewswire/ — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches o
Iveric Bio stock surges on Astellas Pharma takeover deal
03:13pm, Monday, 01'st May 2023
Iveric Bio Inc shares climbed 16% to $38.01 on Monday after the US drugmaker agreed to be acquired by Japan's Astellas Pharma for $40 per share in cash or total consideration of about $5.9 billion.
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
10:01am, Monday, 01'st May 2023
Astellas Pharma snapped up Iveric Bio for $5.9 billion in cash, the companies said Monday in an announcement that sent ISEE stock flying. The post Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion
Iveric Bio Stock Surges. It's Being Bought by Astellas for $5.9 Billion.
06:00am, Monday, 01'st May 2023
Japan's Astellas agrees to pay $40 a share for Iveric, citing the potential of the biopharmaceutical company's ophthalmology programs.
Japan's Astellas Pharma to buy Iveric Bio in deal worth $5.9 billion
01:34am, Monday, 01'st May 2023
Astellas Pharma Inc. said Monday that it agreed to acquire Iveric bio Inc. for about $5.9 billion to strengthen its capabilities in the ophthalmology field.
These Are the Top 10 Holdings of David Kim
10:55pm, Monday, 06'th Mar 2023
David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 20
Why Is Iveric Bio (ISEE) Stock Up 25% Today?
02:34pm, Friday, 18'th Nov 2022
Against a relatively flat backdrop for the major equity indices, biotechnology firm Iveric Bio (NASDAQ: ISEE ) provided a decisively positive framework, with shares gaining 25% on Friday afternoon. Ye
IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript
10:42pm, Saturday, 05'th Nov 2022
IVERIC bio, Inc. (NASDAQ:ISEE ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Kathy Galante - SVP, IR & Corporate Communications Glenn Sblendorio - CEO & Director P
